EUVIMEDEUVIMED entdecken
Crossref

Antibiotic resistance, drug prices, and entry

Miaoqing Jia, Ching-To Albert Ma

Economics & Human Biology · 2026

DOI: 10.1016/j.ehb.2026.101616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Economics & Human Biology, 2026. Verfasst von Miaoqing Jia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Sciences, Weill Cornell Medicine, United States of America. Electronic address: mij4018@med.cornell.edu. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Resistance, Microbial, Drug Costs, Drug Industry. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Università Bocconi, Monash University, Academia Sinica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibiotics lose power to kill microbes through excessive use, commonly known as antibiotic resistance, which is modeled by future cost increase from current use. The first best incorporates future cost externality due to current consumption. Resistance and consumer welfare deviate from first best in various market structures. Low prices under competition lead to high consumption and resistance. Competitive managed-care plans use rationing contracts, which partially internalize resistance cost externality by restricting use. A drug monopolist fully internalizes the externality, but sets a high price. We derive necessary and sufficient conditions for higher consumer surplus under monopoly than competition. Facing a potential entrant, an incumbent may consider entry deterrence and accommodation. To deter entry, the incumbent reduces current sales to lower future cost; this alleviates antibiotic resistance. Entry accommodation gives rise to two countervailing effects. First, incumbent and entrant will share the market. The incumbent has less incentive to internalize the cost effect, so raises production and exacerbates resistance. Second, the incumbent makes more profit when its future cost is low, so reduces production and mitigates resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsDrug Resistance, MicrobialDrug CostsDrug IndustryCommerceDrug Resistance, BacterialHumansEconomic Competition

Stichwörter der Autor:innen

Antibiotic resistanceCompetitionCournotDrug pricesEntryMonopolyPharmaceuticals

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Population Health Sciences, Weill Cornell Medicine, United States of America. Electronic address: mij4018@med.cornell.edu.
  • Department of Economics, Boston University, United States of America. Electronic address: ma@bu.edu.

Förderung

  • Università Bocconi
  • Monash University
  • Academia Sinica
  • Hong Kong Baptist University
  • Universität Hamburg
  • Chinese University of Hong Kong
  • University of Sydney
  • Boston University

Zitieren

APA

Jia, M., & Ma, C. A. (2026). Antibiotic resistance, drug prices, and entry. Economics & Human Biology. https://doi.org/10.1016/j.ehb.2026.101616

Vancouver

Jia M, Ma CA. Antibiotic resistance, drug prices, and entry. Economics & Human Biology. 2026. doi:10.1016/j.ehb.2026.101616

BibTeX
@article{Jia2026,
  author = {Jia, Miaoqing and Ma, Ching-To Albert},
  title = {Antibiotic resistance, drug prices, and entry},
  journal = {Economics & Human Biology},
  year = {2026},
  doi = {10.1016/j.ehb.2026.101616}
}
Kostenlos starten →